Is ABT or GILD cheaper?

On trailing earnings, GILD is cheaper: ABT trades at a 24.56 P/E and GILD at 17.11.

Which has grown faster, ABT or GILD?

Over the past five years, ABT grew revenue faster — ABT at a 3.87% CAGR versus GILD at 3.07%.

Does ABT or GILD pay a bigger dividend?

ABT yields 2.77% and GILD yields 1.91% based on trailing dividends and the latest price.

Is ABT or GILD more profitable?

GILD runs the higher net margin — ABT at 13.91% versus GILD at 30.99%.

Which has been the better investment, ABT or GILD?

Over the past 10-year, ABT delivered the higher annualized total return — ABT at 10.72% versus GILD at 7.79%. Past performance doesn't predict future results.

Abbott Laboratories (ABT) vs Gilead Sciences, Inc. (GILD)

GILD leads on 13 of 17 compared metrics.

A side-by-side comparison of Abbott Laboratories and Gilead Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Gilead Sciences, Inc.

$155.93B

$125.59Healthcare

Total return — ABT vs GILD

growth of $100 · last 30y

ABT +804.4%GILD +13408.8%GILD compounded faster

Log scale — wide-divergence pair

ABT GILD

ABT vs GILD: by the numbers

•GILD is the larger company ($155.93B vs $153.59B market cap).
•GILD trades at the lower earnings multiple (17.11 vs 24.56 P/E).
•GILD converts more revenue to profit (30.99% vs 13.91% net margin).
•ABT grew revenue faster over the past five years (3.87% vs 3.07% CAGR).
•ABT pays the higher dividend yield (2.77% vs 1.91%).

Which is better, ABT or GILD?

Metric tally: ABT 4 · GILD 13

It depends on what you're optimizing for:

ValueGILD(lower P/E)

GrowthABT(faster 5Y revenue CAGR)

IncomeABT(higher dividend yield)

QualityGILD(higher ROIC)

Valuation

Metric	ABT	GILD
P/E ratio	24.56	17.11●
Forward P/E	14.56	13.00●
P/S ratio	3.41●	5.30
P/B ratio	2.96●	6.70
PEG ratio	2.99	0.01●
EV / EBITDA	17.30	12.91●
FCF yield	4.79%	6.49%●

Profitability

Metric	ABT	GILD
Gross margin	56.38%	79.35%●
Operating margin	18.17%	38.26%●
Net margin	13.91%	30.99%●
ROE	12.06%	39.19%●
ROIC	8.43%	21.53%●

Dividends

Metric	ABT	GILD
Dividend yield	2.77%●	1.91%
Payout ratio	65.24%	35.09%

Growth (annualized)

Metric	ABT	GILD
Revenue CAGR (5Y)	3.87%●	3.07%
EPS CAGR (5Y)	8.22%	133.83%●
FCF CAGR (5Y)	-0.61%	3.30%●
Total return CAGR (5Y)	-2.49%	17.06%●

Frequently asked

Which is better, ABT or GILD?: It depends on your goal. value: GILD (lower P/E); growth: ABT (faster 5Y revenue CAGR); income: ABT (higher dividend yield); quality: GILD (higher ROIC). Across all compared metrics, GILD leads 13 to 4.
Is ABT or GILD cheaper?: On trailing earnings, GILD is cheaper: ABT trades at a 24.56 P/E and GILD at 17.11.
Which has grown faster, ABT or GILD?: Over the past five years, ABT grew revenue faster — ABT at a 3.87% CAGR versus GILD at 3.07%.
Does ABT or GILD pay a bigger dividend?: ABT yields 2.77% and GILD yields 1.91% based on trailing dividends and the latest price.
Is ABT or GILD more profitable?: GILD runs the higher net margin — ABT at 13.91% versus GILD at 30.99%.
Which has been the better investment, ABT or GILD?: Over the past 10-year, ABT delivered the higher annualized total return — ABT at 10.72% versus GILD at 7.79%. Past performance doesn't predict future results.

Go deeper

Full ABT analysis Full GILD analysis Interactive comparison tool

Dig into the metrics

Abbott Laboratories P/E ratio Gilead Sciences P/E ratio Abbott Laboratories dividend yield Gilead Sciences dividend yield Abbott Laboratories ROE Gilead Sciences ROE Abbott Laboratories operating margin Gilead Sciences operating margin Abbott Laboratories revenue growth Gilead Sciences revenue growth Abbott Laboratories free cash flow Gilead Sciences free cash flow

Abbott Laboratories & Gilead Sciences appear in these rankings

Highest Dividend Yield Stocks Dividend Aristocrats Highest ROE Stocks Highest ROIC Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.